1. Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan.
- Author
-
Tani, Yuta, Takita, Morihito, Kobashi, Yurie, Wakui, Masatoshi, Zhao, Tianchen, Yamamoto, Chika, Saito, Hiroaki, Kawashima, Moe, Sugiura, Sota, Nishikawa, Yoshitaka, Omata, Fumiya, Shimazu, Yuzo, Kawamura, Takeshi, Sugiyama, Akira, Nakayama, Aya, Kaneko, Yudai, Kodama, Tetsuhiko, Kami, Masahiro, and Tsubokura, Masaharu
- Subjects
BOOSTER vaccines ,IMMUNE response ,MEDICAL personnel ,HUMORAL immunity ,VACCINATION ,SARS-CoV-2 ,CELLULAR immunity - Abstract
Booster vaccination reduces the incidence of severe cases and mortality related to COVID-19, with cellular immunity playing an important role. However, little is known about the proportion of the population that has achieved cellular immunity after booster vaccination. Thus, we conducted a Fukushima cohort database and assessed humoral and cellular immunity in 2526 residents and healthcare workers in Fukushima Prefecture in Japan through continuous blood collection every 3 months from September 2021. We identified the proportion of people with induced cellular immunity after booster vaccination using the T-SPOT.COVID test, and analyzed their background characteristics. Among 1089 participants, 64.3% (700/1089) had reactive cellular immunity after booster vaccination. Multivariable analysis revealed the following independent predictors of reactive cellular immunity: age < 40 years (adjusted odds ratio: 1.81; 95% confidence interval: 1.19–2.75; p-value: 0.005) and adverse reactions after vaccination (1.92, 1.19–3.09, 0.007). Notably, despite IgG(S) and neutralizing antibody titers of ≥500 AU/mL, 33.9% (349/1031) and 33.5% (341/1017) of participants, respectively, did not have reactive cellular immunity. In summary, this is the first study to evaluate cellular immunity at the population level after booster vaccination using the T-SPOT.COVID test, albeit with several limitations. Future studies will need to evaluate previously infected subjects and their T-cell subsets. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF